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the American Heart Association/American College of Cardiology/Heart Rhythm Society AF guidelines have promoted the utility of the CHA2DS2-VASc over the CHADS2 score to identify patients who are at truly low risk for STE events.
[48] Additionally, the CHA2DS2-VASc score takes into consideration risk factors that were not previously accounted for (i.e., female sex, age 65-75 years, vascular disease). Importantly, the independent risk of stroke in patients with HF
complicating AF may be underestimated by commonly used risk stratification schemes. Specifically, similarly scored individual risk factors for STE events in AF do not imply exactly equivalent actual additional risk.
[37-40, 53, 54] Notably, in the Framingham Heart Study, HF carried a fourfold risk of STE events per year, whereas hypertension and coronary heart disease (CHD) implied only three times and twice the risk, respectively.
[36] Thus, many experienced clinicians elect to anticoagulate patients with HF as their only CHA2DS2-VASc risk factor, using either VKA or a NOAC, if the bleeding risk is low. When making this decision, the HAS-BLED score can be utilized to assess the bleeding risk of anticoagulation. [55] Clinical trials assessing the risk of STE events in AF have used various definitions for the diagnosis of HF. A C C E P T E D M A N U S C R I P T finding, given data from registry populations and study subsets suggesting adverse outcomes with HF and prevalent AF. [6-9, 12, 16] Critics have argued that imperfect effectiveness of normal sinus rhythm (NSR) maintenance and adverse effects of current pharmacological therapy potentially limited benefit of rhythm control in these studies. [77] However, similar NYHA class and 6-minute walk test (6MWT) distance were observed whether a rate-control or rhythm-control strategy was pursued (p=NS for both). [77] The management strategy of NSR restoration with AADs is appropriate in HF patients with symptomatic AF.
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Of the available AADs, only amiodarone and dofetilide are recommended in patients with LV dysfunction and/or clinical HF (see Table 1 ).
[48] Amiodarone is the most effective AAD, but its potency is at best 60% at one year and its use carries a non-negligible risk of adverse Newer AADs including vernakalant, budiodarone, and adjuvant ranolazine (which was used with dronedarone in the HARMONY trial) are also being investigated, and may meet the promise of efficacy with improved safety. However, current trials examining these agents do not include patients with significant LV dysfunction. A C C E P T E D M A N U S C R I P T Additionally, a meta-analysis of seven large RCTs of BB found similar results: a reduced risk of AF (OR 0.73) among 11,952 patients with HF. [99] In sum, therefore, the evidence suggests that BB can reduce the incidence of AF in HF patients, but they do not seem to be as effective in preventing major adverse CV outcomes in AF patients with chronic HFrEF.
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The authors have cited several plausible explanations for this differential effect of BB, including adverse impact of slow heart rate during AF, or that AF is simply a marker of a worse clinical condition in which improvement is more difficult to achieve. [97] In patients with LVEF <35% and mild symptoms (NYHA II), the addition of the aldosterone blocker eplerenone to an optimal HF regimen demonstrated further reduction in new onset AF (HR 0.58, P=0.034).
[100] The utility of upstream therapy for the primary prevention of AF in patients with known LV dysfunction should not be disregarded. While further randomized data are needed, the experience with these now conventional HF therapies supports their role in primary prevention of AF in HF.
Catheter-Based AF Ablation in HF
In part due to the risks of AADs and its incomplete success in maintaining NSR, catheter-based ablation (CA) has emerged as a formidable therapeutic option in the management of AF. [101] Current data regarding CA support its safety, efficacy, and utility in alleviating symptoms and improving QoL. [102, 103] However, whether CA reduces
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all-cause mortality, stroke, and HF is still under investigation. [104] Most patients included in CA trials are relatively young, with little co-morbidity, and normal to mildly reduced LVEF. [102] However, in two P=0.001). [112] Clearly, CA is rapidly evolving at present, and improvements in the efficacy and safety of this procedure occur frequently. [113] Numerous studies have demonstrated the superiority of CA over medical therapy in maintaining NSR in structurally normal hearts. The initial experience suggests that these advantages may also extend to patients with HFhowever at this time the number of randomized studies remains small.
Unquestionably, additional prospective data describing CA-related mortality and morbidity in patients with LV dysfunction are needed.
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